文献速递神经免疫

COVID-19疫苗接种后吉兰-巴雷综合征风险:全国性自我对照病例系列研究

Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study.
PubMed 文献 · Neurology · 2023-10-03

该研究基于法国国家健康数据系统,采用自我对照病例系列设计,分析2020年12月27日至2022年5月20日期间12岁及以上GBS住院患者。结果显示首剂ChAdOx1-S疫苗后1-42天GBS相对发生率为2.5(95%CI 1.8-3.6),Ad26.COV2.S疫苗为2.4(95%CI 1.2-5.0);mRNA疫苗除12-49岁组第二剂mRNA-1273后相对发生率2.6(95%CI 1.2-5.5)外,其余均无显著升高。

要点

  • 首剂ChAdOx1-S后1-42天GBS相对发生率2.5(95%CI 1.8-3.6),归因病例6.5例/百万人。
  • Ad26.COV2.S疫苗后GBS相对发生率2.4(95%CI 1.2-5.0),归因病例5.7例/百万人。
  • mRNA疫苗除12-49岁组第二剂mRNA-1273后相对发生率2.6(95%CI 1.2-5.5)外,其余均无显著升高。

核心结论

  • 首剂ChAdOx1-S和Ad26.COV2.S疫苗接种后GBS风险增加;在法国人群水平上,mRNA疫苗接种后GBS风险无统计学显著增加,这对持续和未来使用mRNA加强疫苗接种具有 reassuring 意义。

研究设计与样本

  • 基于法国国家健康数据系统链接COVID-19疫苗数据库的全国性自我对照病例系列研究,分析2020年12月27日至2022年5月20日期间12岁及以上GBS住院患者,比较接种后1-42天与基线期的GBS相对发生率,并按时期、年龄组、性别及SARS-CoV-2或常见急性感染进行调整和分层。

主要发现

  • 在58,530,770名12岁及以上人群中,88.8%至少接种1剂COVID-19疫苗,研究期间2,229例因GBS住院,患者中位年龄57岁,60%为男性。
  • 首剂ChAdOx1-S后1-42天GBS相对发生率为2.5(95%CI 1.8-3.6),Ad26.COV2.S疫苗单剂后为2.4(95%CI 1.2-5.0)。
  • 估计每百万人接受首剂ChAdOx1-S后归因GBS病例6.5例,Ad26.COV2.S疫苗为5.7例。
  • 除12-49岁年龄组第二剂mRNA-1273疫苗后相对发生率2.6(95%CI 1.2-5.5)外,mRNA疫苗的其他相对发生率估计均未发现显著升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Guillain-Barré syndrome (GBS) has been inconsistently associated with some coronavirus disease 2019 (COVID-19) vaccines. We aimed to quantify the risk of GBS according to the type of COVID-19 vaccine in a large population. METHODS: Using the French National Health Data System linked to the COVID-19 vaccine database, we analyzed all individuals aged 12 years or older admitted for GBS from December 27, 2020, to May 20, 2022. We estimated the relative incidence (RI) of GBS within 1-42 days after vaccination up to the first booster dose compared with baseline periods using a self-controlled case series design. We then derived the number of cases attributable to the vaccination. Analyses were adjusted for the period and stratified by age group, sex, and for the presence of severe acute respiratory syndrome coronavirus 2 or common acute infections. RESULTS: Of 58,530,770 people aged 12 years or older, 88.8% received at least 1 COVID-19 vaccine dose and 2,229 were hospitalized for GBS during the study period. Patients had a median age of 57 years, and 60% were male patients. The RI of GBS between 1-42 days was 2.5 (95% CI 1.8-3.6) for the first dose of ChAdOx1-S and 2.4 (95% CI 1.2-5.0) for the unique dose of Ad26.COV2.S vaccine. We estimated 6.5 attributable GBS cases per million persons having received a first dose of ChAdOx1-S and 5.7 cases per million for the Ad26.COV2.S vaccine. Except for the age group of 12-49 years after the second dose of the messenger RNA (mRNA)-1273 vaccine (RI 2.6, 95% CI 1.2-5.5), none of the RI estimates were found significantly increased for the mRNA vaccines. DISCUSSION: In summary, we found increased risks of GBS after the first administration of ChAdOx1-S and Ad26.COV2.S vaccines. In this comprehensive assessment at the French population level, there was no statistically significant increase in the risk of GBS after the administration of mRNA vaccines. This is reassuring in the context of the ongoing and future use of mRNA-based booster vaccination.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Le Vu S, Bertrand M, Botton J, et al. Risk of Guillain-Barré Syndrome Following COVID-19 Vaccines: A Nationwide Self-Controlled Case Series Study. Neurology. 2023. PMID: 37788935. doi:10.1212/WNL.0000000000207847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。